India to Egypt: Bevacizumab Export Trade Route

The India to Egypt Bevacizumab corridor is one of India's established pharmaceutical export routes, with 16 shipments documented worth a combined $718.4K USD. The route is dominated by BIOCON BIOLOGICS INDIA LIMITED, which alone accounts for roughly 78% of all export value, reflecting the consolidated nature of India's bevacizumab manufacturing sector.

Across 7 active suppliers, the average shipment value stands at $44.9K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 77% of all shipments, consistent with bevacizumab's non-urgent bulk-order profile.

Shipment activity peaks during July–September, with an average transit time of 25 days port-to-port. The route has recorded an annual growth rate of 30.9%, placing it at rank #17 among India's top bevacizumab export destinations globally.

On the import side, key buyers of Indian bevacizumab in Egypt include BIOCON BIOLOGICS UK LIMITED, ROYAL MEDICAL AMREYA PUBLIC FREE, ROYAL PHARMACEUTICALS L L FZ and 7 others. BIOCON BIOLOGICS UK LIMITED is the single largest importer with 1 shipments valued at $561.7K USD.

India's bevacizumab exports to Egypt are driven primarily by a handful of large-scale manufacturers. BIOCON BIOLOGICS INDIA LIMITED with 7 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 7 active exporters signals a competitive but concentrated market — buyers in Egypt benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — BIOCON BIOLOGICS INDIA LIMITED, HEALTHBIOTICS PRIVATE LIMITED, AL-ROYAL PHARMACEUTICAL PRIVATE LIMITED — together account for 93% of total trade value on this route. The average shipment value of $44.9K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as abevmy 400 bevacizumab injection 1 vial 16ml as per invoice and packing list and bevacizumab 400mg inj b/n- bf22002942, b, suggesting that buyers in Egypt tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, BIOCON BIOLOGICS UK LIMITED is the largest importer with 1 shipments worth $561.7K USD — representing 78% of all bevacizumab imports from India on this route. A total of 10 buyers are active on this corridor.